1. Home
  2. DOUG vs AGEN Comparison

DOUG vs AGEN Comparison

Compare DOUG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

HOLD

Current Price

$1.74

Market Cap

162.3M

Sector

Real Estate

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.10

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOUG
AGEN
Founded
1911
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.3M
147.4M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
DOUG
AGEN
Price
$1.74
$3.10
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
339.8K
596.6K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
118.68
100.00
EPS
N/A
1.02
Revenue
$955,578,000.00
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.98
Revenue Growth
N/A
89.95
52 Week Low
$1.53
$2.71
52 Week High
$3.19
$7.34

Technical Indicators

Market Signals
Indicator
DOUG
AGEN
Relative Strength Index (RSI) 47.69 44.00
Support Level $1.69 $2.93
Resistance Level $1.86 $3.15
Average True Range (ATR) 0.06 0.22
MACD 0.00 -0.00
Stochastic Oscillator 44.83 38.70

Price Performance

Historical Comparison
DOUG
AGEN

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: